Given that dogs develop NSCLC and are a good in vivo model for studying the effects of PPAR-γ agonists, it is critical to understand the expression of this protein and possible epigenetic control in the normal canine lung and canine lung cancer. This evidence concerns the gene PPARG and lung carcinoma.